{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-102700","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.566647+00:00","generated_at":"2026-05-15T12:55:53.452746+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Gyre Therapeutics FY2025 revenue up 10% to $116.6M; net income down; guides FY2026 lower","bullets":["Full-year 2025 revenue $116.6M (+10.2% YoY); net income $9.9M vs $17.9M; non-GAAP adj. net income $18.9M vs $16.9M.","Q4 2025 revenue $37.2M (+33.3% YoY); net loss $1.4M vs income $0.6M; non-GAAP adj. net income $4.3M vs $1.1M.","FY2026 revenue guidance $100.5M–$111.0M, a decline of 4.8%–13.8% vs 2025, citing regulatory priorities and market dynamics.","Agreed to acquire Cullgen in ~$300M all-stock deal; transaction expected to close Q2 2026, adding protein degrader platform.","Hydronidone NDA for conditional approval in China (CHB fibrosis) planned H1 2026; U.S. IND for MASH fibrosis targeted in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-102700","json":"https://secwatch.observer/filing/0001193125-26-102700.json","markdown":"https://secwatch.observer/filing/0001193125-26-102700.md","text":"https://secwatch.observer/filing/0001193125-26-102700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000119312526102700/0001193125-26-102700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000119312526102700/gyre-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:55:53.452746+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"752895226dd3dc3e10ccba5ff2d7d1852d5c1051","claim":"GYRE THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2025 results: revenue $116.6 million. Guidance reaffirmed.","evidence_excerpt":"Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000119312526102700/0001193125-26-102700-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Revenue","value":"$116.6 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}